Clinical Trial Search

Primary: Change in Lip Vessel's Thickness — 0.833; 0.360 µm

Primary: Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) — 23; 21 genes

Primary: Nasal Tip Projection — 0.601 ratio

Primary: Mean Change From Baseline in Corneometer Measurements — 23.5; 24.2; 2.4; -0.6 Arbitrary units — p=<0.0001

Primary: First Impressions — 46.756; 27.769; 46.391; 34.404 score on a scale

Primary: Mean Change From Baseline in Corneometry Value at Each Post-treatment Timepoint — 23.1; 23.3; 7.8; 0.1 Arbitrary units — p=<0.0001

Primary: Change in TLFS Score (Teoxane Lip Fullness Scale) Between Baseline and Week 12 After Last Treatment of RHA®3 Versus Control Device, as Assessed by the BLE — 1.0; 0.8…

Primary: Percentage of Participants Assessed as At Least 1-point Improvement From Baseline on Medicis Lip Fullness Scale (MLFS) — 94.7; 94.7 percentage of participants

Primary: Hydration Level — 53.19; 46.75 AU (arbitrary unit) — p=<0.05

Primary: Correct Identification of Before and After Photographs — 20 Participants

Primary: Investigator Assessment of the Subject's Overall Lip Fullness on the 4-point Lip Fullness Scale — 93.2 percentage of responders

Primary: Month 3 Overall Lip Fullness Scale Responder Rate Based on Independent Central Reviewer's Assessment — 34.1; 29.3 Percentage of subjects

Primary: Assess Effectiveness of the Treatment Using the Medicis Lip Fullness Scale (MLFS) — 1.8; 1.7; 1.8; 1.8 Change in MLFS score from baseline

Primary: Subject Rating of the Natural Look and Feel of the Lips — 52.5; 35.6; 11.9; 0 Percentage of subjects

Primary: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values — 17.3; 17.9; 19.3; 18.4 Ratio

Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids

Primary: Percentage of Participants With Response — 92.6; 28.9 Percentage of Participants

Primary: Arithmetic Mean SPF Values — 13.9; 16.1; 14.3; 15.8 Ratio

Primary: Percentage of Participants With a ≥1-point Increase (Improvement) on the Evaluating Investigator's (EI's) Assessed 5-point Lip Fullness Scale (LFS) — 0; 84.7 percentage…

Primary: Percentage of Participants With a ≥ 1-point Improvement (Increase) in the Lip Fullness Scale (LFS2) Compared to Baseline Assessment at Day 30 — 93.2 percentage of…

Primary: Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated Versus (vs.) Untreated Side at Day 29 — -1.90; -0.12 Micro meter (µm) — p=0.0638

Primary: Change in Overall Lip Fullness Grading Scale — 1.52; 1.53 score on a scale

Primary: Percentage of Subjects With ≥1-Point Improvement on the Investigator Assessed 5-point Lip Fullness Scale 2 (LFS2) — 79.1; 26.1 Percentage of Subjects

Primary: Change in Tear Lipid Layer Thickness — 4.8; 8.8 nm

Primary: Number of Participants With Adverse Events With the Use of Restylane Silk With Lidocaine — 11 Participants

Primary: Number of Participants With a Change in Clearance From Baseline — 1; 1; 9; 4 Participants

Primary: Responder Rate in Lip Volume Improvement — 55; 52; 107; 53 Participants

Primary: Change From Baseline in Activities of Daily Living (ADL) at 18 Months — -11.58; -13.45 units on a scale — p=0.82

Primary: GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 8 After Treatment — 86.2; 86.7 percentage improved subjects

Primary: Global Response to Therapy — 16; 41 eyes — p=.001